Cash not forcing Oclassen IPO

With break-even cash flow from product sales and a full pipeline of later-stage products in the clinic, Oclassen Pharmaceuticals Inc. has seemed especially fitted to the increasingly rigorous demands of the Street.

But its proposed IPO of 3 million shares at $17 to $19 per share, which was registered in January, has languished in the stale offerings market and the company now must consider whatever effects may result